• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Delta Air eyes mid single-digit revenue growth in 2025 with premium travel in focus

by November 20, 2024
written by November 20, 2024

(Reuters) – Delta Air Lines (NYSE:DAL) said on Wednesday it expects 2025 revenue to grow by a mid single-digit percentage as it strengthens its bet on premium travel, a major revenue driver for the carrier.

The airline added that affluent customers were thriving with leisure travel being the highest priority purchase for high-income households.

Premium travel has been on the rise since the pandemic, with consumers preferring to pay extra dollars for amenities such as more comfortable seats.

Premium seating, which previously depended heavily on corporate bookings, is now seeing increased interest from individual travelers.

Delta Air said it is targeting profit per share to increase 10% in the next three to five years, and expects operating margins to be in the mid-teens percentage.

The Atlanta-based company expects its high-margin premium offerings to outpace its main cabin by 2027.

That opens up avenues for the carrier to grow revenue through non-ticket sources such as airline-branded credit card fees, checked bags and extra legroom.

Delta also forecast 2025 capacity growth between 3% and 4%. The carrier’s shares fell nearly 1% before the bell suggesting investor worries about effects of excess capacity on air fares.

An excess supply of airline seats in the U.S. market during the summer travel season had forced carriers to discount fares to fill their planes, hurting their earnings.

However, measures taken by airlines to moderate capacity growth have since aided pricing power.

Delta Air’s investor day is scheduled on Wednesday where it is expected to provide further details on its long-term financial targets.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
China’s Pony AI seeks up to $4.55 billion valuation in upsized US IPO
next post
Pfizer names oncology head Chris Boshoff as R&D chief

You may also like

Adani, Ambani news units sue OpenAI over copyright,...

March 13, 2026

China’s DeepSeek sets off AI market rout

March 13, 2026

BASF results down on impairments, restructuring

March 13, 2026

Nasdaq futures tumble as China’s AI push rattles...

March 13, 2026

European chipmakers slump as traders gauge DeepSeek AI...

March 13, 2026

Fuji Media, rocked by sexual misconduct allegations, says...

March 13, 2026

China Vanke’s CEO, chairman resign amid growing liquidity...

March 13, 2026

Italy’s MPS shares fall ahead of Mediobanca board...

March 13, 2026

UMG shares rally after new multi-year pact with...

March 13, 2026

British Land stock drops following stake sale

March 13, 2026
Sign up and get the scoop before anyone else—fresh updates, and secret deals, all wrapped up just for you. We're talking juicy tips, fun surprises, and invites to events you actually want to go to. Don’t just watch from the sidelines—jump in and be part of the magic!








    By signing up, you're cool with getting emails from us. Don’t worry — your info stays safe, sound, and strictly confidential. No spam, no funny business. Just the good stuff.

    Recent Posts

    • Trump administration alleges Nike discriminated against white workers

      March 13, 2026
    • Landmark trial accusing social media companies of addicting children to their platforms begins

      March 13, 2026
    • Retail operator of outdoor sportswear pioneer Eddie Bauer files for bankruptcy

      March 13, 2026
    • Cardi B’s cameo in Bad Bunny’s Super Bowl halftime show leads to dispute on prediction markets

      March 13, 2026

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (690)
    • Stock (6,426)

    Latest News

    • Trump administration alleges Nike discriminated against white workers
    • Landmark trial accusing social media companies of addicting children to their platforms begins

    Popular News

    • US government agencies fail to meet fleet EV targets, GAO report says
    • GSK CEO plans more deals, focuses on cancer medicines

    About The Significant deals

    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Copyright © 2026 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy